Leica Biosystems Celebrates 2,000 Global Digital Pathology Scanner Installations
VISTA, California, Sept. 21, 2017 /PRNewswire/ -- Leica Biosystems announced that it has delivered and installed its 2,000th digital pathology scanner. This is a key milestone for both the company and the digital pathology industry it pioneered. Leica Biosystems has been the digital pathology leader ever since it launched its first Aperio line scanners.
"This is quite an achievement. By leveraging our commercial presence in over 100 countries, we have now built an installed base of 2,000 systems. China and North America stand out with over 400 installs over the last 24 months alone," stated Jerome Clavel, Vice President and General Manager of Pathology Imaging, at Leica Biosystems. "The digital pathology market is growing very quickly. Leica Biosystems has always had a commitment to rapid and sustained innovation in this space. We bring to bear deep product expertise, as well as comprehensive IT implementation skills for seamless customer installs."
Leica Biosystems offers a broad portfolio of leading-edge brightfield and fluorescent digital pathology scanners including Aperio AT2, Aperio AT Turbo, Aperio CS2, Aperio LV1, and Aperio VERSA among others.
About Leica Biosystems:
Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.
Media Contact(s): Courtney Hill, Global Brand Marketing Specialist
GlobalMarketing@leicabiosystems.com +1-847-821-3537
Photo - http://mma.prnewswire.com/media/559115/Leica.jpg
Share this article